That stock News

Lawyers for cheaper generic alternative manufacturer Reckitt, Gaviscon Pinewood, laboratories are considering to make a claim after admitted Reckitt "reached United Kingdom and European competition law", eliminating Gaviscon Original list of NHS prescription drugs in 2005.

The OFT claimed that Reckitt withdrew Gaviscon Original when its patent had expired but before a generic name has been added to the list of NHS and Gaviscon Advance, which is still protected by patent, left on the list.

When the NHS doctors find a brand drug, their software shows a generic alternative if there is one, allowing pharmacists dispensing medicines less chers.Toutefois when typed physicians Gaviscon they found only the Advance version, so no generic alternative medicine Acidex of pinewood, was offered.

Initially said Reckitt shares are legitimate, but have now has changed his position and allowed to break the laws on competition.

"While the company believes in the time it was acting in the law, as it is always our intention, we respect the opinion of the OFT in this case and agreed to resolve" Reckitt said, adding that the offence "took place a number of years in a very complex area of the Act on competition, on which there were only more recently been clarify case."

The OFT has studied last year after a snitch Reckitt talks to the BBC and a complaint Pinewood Newsnight.

View the original article here